Lenalidomidum Stada Arzneimittel Ag (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, leading to the ubiquitination and degradation of transcription factors Ikaros and Aiolos. This action modifies cytokine production, inhibits angiogenesis, and enhances immune‑mediated anti‑tumor activity, thereby reducing proliferation of malignant plasma cells.

The specific dose of lenalidomide is individualized by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Dosing regimens are detailed in the product’s prescribing information and should be followed exactly as directed by a qualified healthcare professional.

Lenalidomide is classified as pregnancy category X because it is teratogenic and can cause fetal harm. It is contraindicated in pregnancy, and effective contraception is required for both male and female patients of reproductive potential. Use during breastfeeding is not recommended due to potential secretion in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and required import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class and is structurally related to thalidomide. Compared with thalidomide, lenalidomide generally shows greater potency, a more favorable side‑effect profile, and reduced neurotoxicity, while retaining anti‑angiogenic and immunomodulatory properties. Both agents are used in similar hematologic malignancies, but choice depends on efficacy, tolerability, and regulatory approval.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect from moisture, excessive heat, and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Lenalidomide is administered orally, usually once daily on a schedule defined by the prescriber (e.g., 21 days on followed by 7 days off). Tablets should be swallowed whole with water and taken at the same time each day, preferably with or without food as directed in the prescribing information.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia or other cytopenias that increase infection risk, and the potential development of secondary primary malignancies. Patients should be monitored regularly for signs of clotting, infection, and new cancer diagnoses.

Lenalidomide should not be used by individuals who are pregnant, planning to become pregnant, or not using effective contraception. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any component of the formulation, and caution is advised in those with severe renal impairment or uncontrolled infections.